Author: | Sabbatini, P. |
Article Title: | New agents and new formulations for the treatment of ovarian cancer |
Keywords: | vasculotropin; cancer survival; vascular endothelial growth factor a; survival rate; unclassified drug; thalidomide; clinical trial; cancer localization; cancer recurrence; bevacizumab; cisplatin; erlotinib; cancer combination chemotherapy; drug efficacy; drug potentiation; drug safety; note; paclitaxel; drug megadose; antineoplastic agent; colorectal cancer; ovarian neoplasms; carboplatin; ovary cancer; antineoplastic combined chemotherapy protocols; recurrence; cyclophosphamide; vasculotropin inhibitor; angiogenesis; cetuximab; survival time; antibodies, monoclonal; gefitinib; vatalanib; predictive value of tests; remission induction; tamoxifen; cancer relapse; intestine perforation; ca 125 antigen; ca-125 antigen; trabectedin; quinazolines; metabolic disorder; drug delivery system; electrolyte disturbance; drug formulation; dioxoles; isoquinolines; oregovomab; tetrahydroisoquinolines; 1 acylglycerophosphocholine acyltransferase; endothelial cell growth factor; hyb 2055; imoxine |
Journal Title: | Clinical Advances in Hematology & Oncology |
Volume: | 3 |
Issue: | 11 |
ISSN: | 1543-0790 |
Publisher: | Millennium Medical Publishing, Inc |
Date Published: | 2005-11-01 |
Start Page: | 840 |
End Page: | 842 |
Language: | English |
PUBMED: | 16491624 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 24 October 2012" - "Source: Scopus" |